Group 1 - In August, the A-share market experienced a strong rally, with the Shanghai Composite Index rising by 7.97%, the Shenzhen Component Index by 15.32%, and the ChiNext Index by 24.13% [1] - Among 1,030 comparable ordinary equity funds, 979 funds reported positive performance in August, accounting for 95%, with only 48 funds declining [1] - The top-performing funds were the Fuqun Internet Technology Equity Fund A and C, which achieved returns of 41.91% and 41.84%, respectively, marking them as the only funds to exceed 40% growth in August [1] Group 2 - The top ten holdings of the Fuqun Internet Technology Equity Fund in Q2 included stocks such as Zhongji Xuchuang, Tencent Holdings, and Xiaomi Group, with Zhongji Xuchuang and Xinyisheng being key drivers in the recent AI market surge [2] - Zhongji Xuchuang and Xinyisheng saw significant monthly stock price increases of 63.1% and 88.26% in August, respectively, while other notable stocks like Ruixinwei and Tianfu Communication also experienced substantial gains of over 52% and 87% [2] - Several other equity funds, including the GF Advanced Manufacturing Equity Fund and the Fuqun New Emerging Industries Equity Fund, also reported gains exceeding 35% in August [2] Group 3 - The Fuqun New Emerging Industries Equity Fund is managed by Sun Quan, who has extensive experience in industry research and fund management since joining Fuqun Fund Management in 2015 [3] - The Hai Fuyitong Electronic Information Media Fund, managed by Wu Hao, also has a strong track record, holding similar key stocks in Q2 as the Fuqun Internet Technology Equity Fund [3] - In contrast, pharmaceutical-themed funds faced declines, with all six funds that dropped over 5% being in this category, indicating a significant shift in market sentiment [4] Group 4 - The Shenyuan Lingshin Pharmaceutical Pioneer Fund C and A recorded declines of -9.52% and -9.48%, respectively, making them the worst-performing ordinary equity funds in August [4] - Despite the downturn in August, these funds still achieved positive returns year-to-date due to strong performance earlier in the year [4] - Other pharmaceutical funds, such as the Golden Eagle Medical Health Equity Fund and Dongwu Medical Service Equity Fund, also reported declines of 8.18% and 5.87% [4]